US 2024/0392012 A1 · Antibodies Directed to TIE-2 and Methods of Use

Abstract

The invention relates to anti-Tie2 antibodies and methods of using the same.

Claims36

Dependent claims

-37. (canceled)

A method of treating a Tie2 dysregulated disease in a subject in need thereof, the method comprising administering to the subject an isolated anti-Tie2 antibody, or an antigen-binding fragment thereof, comprising three heavy chain complementarity-determining regions (CDR H1-3) and three light chain CDRs (CDR L1-3) as follows:

HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3
SEQ
SEQ
SEQ
SEQ
SEQ
SEQ
ID No.
ID No.
ID No.
ID No.
ID No.
ID No.
(i)
1
41
81
121
161
201;
(ii)
2
42
82
122
162
202;
(iii)
3
43
83
123
163
203;
(iv)
4
44
84
124
164
204;
(v)
5
45
85
125
165
205;
(vi)
6
46
86
126
166
206;
(vii)
7
47
87
127
167
207;
(viii)
8
48
88
128
168
208;
(ix)
9
49
89
129
169
209;
(x)
10
50
90
130
170
210;
(xi)
11
51
91
131
171
211;
(xii)
12
52
92
132
172
212;
(xiii)
13
53
93
133
173
213;
(xiv)
14
54
94
134
174
214;
(xv)
15
55
95
135
175
215;
(xvi)
16
56
96
136
176
216;
(xvii)
17
57
97
137
177
217;
(xviii)
18
58
98
138
178
218;
(xix)
19
59
99
139
179
219;
(xx)
20
60
100
140
180
220;
(xxi)
21
61
101
141
181
221;
(xxii)
22
62
102
142
182
222;
(xxiii)
23
63
103
143
183
223;
(xxiv)
24
64
104
144
184
224;
(xxv)
25
65
105
145
185
225;
(xxvi)
26
66
106
146
186
226;
(xxvii)
27
67
107
147
187
227;
(xxviii)
28
68
108
148
188
228;
(xxix)
29
69
109
149
189
229;
(xxx)
30
70
110
150
190
230;
(xxxi)
31
71
111
151
191
231;
(xxxii)
32
72
112
152
192
232;
(xxxiii)
33
73
113
153
193
233;
(xxxiv)
34
74
114
154
194
234;
(xxxv)
35
75
115
155
195
235;
(xxxvi)
36
76
116
156
196
236;
(xxxvii)
37
77
117
157
197
237;
(xxxviii)
38
78
118
158
198
238;
(xxxix)
39
79
119
159
199
239;
or
(xxxx)
40
80
120
160
200
240.

296 more elements

a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.242 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.243;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.244 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.245;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.246 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.247;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.248 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.249;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.250 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.251;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.252 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.253;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.254 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.255;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.256 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.257;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.258 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.259;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.260 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.261;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.262 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.263;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.264 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.265;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.266 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.267;
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.268 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.269;
or
a heavy chain variable (VH) domain comprising an amino acid sequence of SEQ ID NO.270 and a light chain variable (VL) domain comprising an amino acid sequence of SEQ ID NO.271.

13 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/596,448Filed 5 Mar 2024

Priority

21 Nov 2019

Published

28 Nov 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

C07K 16/2863
Against receptors, cell surface antigens or cell surface determinants: against receptors for growth factors, growth regulators
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides
A61P 27/02
Drugs for disorders of the senses: ophthalmic agents
C12N 5/10
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor: cells…

Family

Application62/938,816Us provisional application · filed 21 Nov 2019

Application16/953,165Division · filed 19 Nov 2020

Application18/596,448Division

US 12,195,542 B2Related patent

US 2021/0155697 A1Published application

US 2024/0392012 A1This patent

From the US filing history. Foreign family members aren’t listed.

Antibodies Directed to TIE-2 and Methods of Use

Life of this patent

Abstract

Claims36

Antibodies Directed to TIE-2 and Methods of Use

Life of this patent

Abstract

Claims36